📣 VC round data is live. Check it out!
- Public Comps
- Creo Medical Group
Creo Medical Group Valuation Multiples
Discover revenue and EBITDA valuation multiples for Creo Medical Group and similar public comparables like Daxor, Pentixapharm Holding, BATM Advanced Communications, Meditera and more.
Creo Medical Group Overview
About Creo Medical Group
Creo Medical Group PLC is a medical device company engaged in providing services in the field of surgical endoscopy. The company has developed a platform called Croma which is an electrosurgical platform to deliver microwave and bipolar radiofrequency through a single accessory port. The reportable segment of the company is the research and development of electrosurgical medical devices relating to the field of surgical endoscopy. Geographically, the company generates a majority of its revenue from United Kingdom and the rest from Europe and the rest of the world.
Founded
2016
HQ

Employees
274
Website
Financials (LTM)
EV
$41M
Valuation Multiples
Start free trialCreo Medical Group Financials
Creo Medical Group reported last 12-month revenue of $10M and negative EBITDA of ($17M).
In the same LTM period, Creo Medical Group generated $5M in gross profit, ($17M) in EBITDA losses, and had net loss of ($2M).
Revenue (LTM)
Creo Medical Group P&L
In the most recent fiscal year, Creo Medical Group reported revenue of $5M and EBITDA of ($30M).
Creo Medical Group is unprofitable as of last fiscal year, with gross margin of 48%, EBITDA margin of (557%), and net margin of (692%).
Financial data powered by Morningstar, Inc.
Creo Medical Group Stock Performance
Creo Medical Group has current market cap of $63M, and enterprise value of $41M.
Market Cap Evolution
Creo Medical Group's stock price is $0.15.
Creo Medical Group share price decreased by 12.9% in the last 30 days, and by 23.8% in the last year.
Creo Medical Group has an EPS (earnings per share) of $-0.09.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $41M | $63M | -0.0% | -12.9% | -25.6% | -23.8% | $-0.09 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCreo Medical Group Valuation Multiples
Creo Medical Group trades at 4.2x EV/Revenue multiple, and (2.4x) EV/EBITDA.
EV / Revenue (LTM)
Creo Medical Group Financial Valuation Multiples
As of May 23, 2026, Creo Medical Group has market cap of $63M and EV of $41M.
Creo Medical Group has a P/E ratio of (25.4x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Creo Medical Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Creo Medical Group Margins & Growth Rates
Creo Medical Group grew revenue by 50% but EBITDA decreased by 35% in the last fiscal year.
In the most recent fiscal year, Creo Medical Group reported gross margin of 48%, EBITDA margin of (557%), and net margin of (692%).
Creo Medical Group Margins
Creo Medical Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Creo Medical Group Operational KPIs
Creo Medical Group's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
Creo Medical Group's Rule of 40 is (51%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Creo Medical Group's Rule of X is 33% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Creo Medical Group Competitors
Creo Medical Group competitors include Daxor, Pentixapharm Holding, BATM Advanced Communications, Meditera, Klea, Pulmonx, Cyclopharm, Bactiguard, Tobii and Xtant Medical.
Most Creo Medical Group public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 6.1x | 7.2x | — | — | |||
| 524.9x | — | (3.1x) | — | |||
| 0.4x | 0.5x | 2.6x | 3.9x | |||
| 0.8x | — | 11.3x | — | |||
| 3.4x | — | 14.9x | — | |||
| 0.7x | 0.7x | (1.7x) | (1.8x) | |||
| 2.9x | 2.8x | (5.8x) | (5.7x) | |||
| 3.0x | 3.1x | 15.1x | 18.5x | |||
This data is available for Pro users. Sign up to see all Creo Medical Group competitors and their valuation data. Start Free Trial | ||||||
Creo Medical Group Funding History
Before going public, Creo Medical Group raised $14M in total equity funding, across 2 rounds.
Creo Medical Group Funding Rounds
Creo Medical Group M&A Activity
Creo Medical Group has acquired 2 companies to date.
Last acquisition by Creo Medical Group was on November 3rd 2020. Creo Medical Group acquired Boucart Medical for $5M (EV/Revenue multiple of ).
Latest Acquisitions by Creo Medical Group
| Description | Boucart Medical is a Ghent-based distributor of gastrointestinal medical devices to hospitals in Belgium and Luxembourg. Founded in 1991, the company represents 30 international suppliers including Cook Medical and Boston Scientific, providing endoscopes, stents, and biopsy tools for endoscopy suites. It supports over 50 hospitals with training programs and inventory management, ensuring compliance with EU MDR regulations. | Albyn Medical is a Dingwall-headquartered manufacturer of single-use devices for urology, gynecology, and endoscopy procedures. Products include catheters, stone retrieval baskets, and insufflation tubing supplied to hospitals across Europe and the US. As part of Laborie, it produces in ISO-certified facilities and distributes through subsidiaries in France and Spain. |
| HQ Country | ||
| HQ City | Brussels | Inverness |
| Deal Date | 3 Nov 2020 | 29 Jul 2020 |
| Valuation | $5M | $27M |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Creo Medical Group acquisitions and their M&A valuation multiples. Start Free Trial | ||
Creo Medical Group Investment Activity
Creo Medical Group has invested in 1 company to date.
Latest investment by Creo Medical Group was on October 4th 2021. Creo Medical Group invested in IQ Endoscopes in their $6M Series A round (EV/Revenue multiple of ).
Latest Investments by Creo Medical Group
| Description | IQ Endoscopes is a product line of single-use flexible endoscopes from Intelligent Endoscopy for gastrointestinal imaging. These devices capture full-length gut visuals during diagnostic and therapeutic procedures, reducing cross-infection risks compared to reusable scopes. Distributed in Europe and beyond, the range includes models for upper and lower GI tracts compatible with standard video processors. | IQ Endoscopes is a product line of single-use flexible endoscopes from Intelligent Endoscopy for gastrointestinal imaging. These devices capture full-length gut visuals during diagnostic and therapeutic procedures, reducing cross-infection risks compared to reusable scopes. Distributed in Europe and beyond, the range includes models for upper and lower GI tracts compatible with standard video processors. |
| HQ Country | ||
| HQ City | — | — |
| Deal Date | 4 Oct 2021 | 22 Dec 2020 |
| Round | Series A | Seed |
| Raised | $6M | $2M |
| Investors | Australian Unity; Creo Medical Group; Development Bank of Wales; Nepcoe Capital Partners | Creo Medical Group; Development Bank of Wales |
| Valuation | undisclosed | undisclosed |
| EV/Revenue | ||
| EV/EBITDA | ||
This data is available for Pro users. Sign up to see all Creo Medical Group investments and their VC round multiples. Start Free Trial | ||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Creo Medical Group
| When was Creo Medical Group founded? | Creo Medical Group was founded in 2016. |
| Where is Creo Medical Group headquartered? | Creo Medical Group is headquartered in United Kingdom. |
| How many employees does Creo Medical Group have? | As of today, Creo Medical Group has over 274 employees. |
| Who is the CEO of Creo Medical Group? | Creo Medical Group's CEO is Craig Jonathan Gulliford. |
| Is Creo Medical Group publicly listed? | Yes, Creo Medical Group is a public company listed on London Stock Exchange. |
| What is the stock symbol of Creo Medical Group? | Creo Medical Group trades under CREO ticker. |
| When did Creo Medical Group go public? | Creo Medical Group went public in 2016. |
| Who are competitors of Creo Medical Group? | Creo Medical Group main competitors include Daxor, Pentixapharm Holding, BATM Advanced Communications, Meditera, Klea, Pulmonx, Cyclopharm, Bactiguard, Tobii, Xtant Medical. |
| What is the current market cap of Creo Medical Group? | Creo Medical Group's current market cap is $63M. |
| What is the current revenue of Creo Medical Group? | Creo Medical Group's last 12 months revenue is $10M. |
| What is the current revenue growth of Creo Medical Group? | Creo Medical Group revenue growth (NTM/LTM) is 59%. |
| What is the current EV/Revenue multiple of Creo Medical Group? | Current revenue multiple of Creo Medical Group is 4.2x. |
| Is Creo Medical Group profitable? | No, Creo Medical Group is not profitable. |
| What is the current EBITDA of Creo Medical Group? | Creo Medical Group has negative EBITDA and is not profitable. |
| What is Creo Medical Group's EBITDA margin? | Creo Medical Group's last 12 months EBITDA margin is (174%). |
| What is the current EV/EBITDA multiple of Creo Medical Group? | Current EBITDA multiple of Creo Medical Group is (2.4x). |
| How many companies Creo Medical Group has acquired to date? | As of May 2026, Creo Medical Group has acquired 2 companies. |
| What was the largest acquisition by Creo Medical Group? | $27M acquisition of Albyn Medical on 29th July 2020 was the largest M&A Creo Medical Group has done to date. |
| What companies Creo Medical Group acquired? | Creo Medical Group acquired Albyn Medical and Boucart Medical. |
| In how many companies Creo Medical Group has invested to date? | As of May 2026, Creo Medical Group has invested in 1 company. |
| What was the last Creo Medical Group investment? | On 4th October 2021 Creo Medical Group invested in IQ Endoscopes, participating in a $6M Series A round, alongside Australian Unity, Development Bank of Wales, and Nepcoe Capital Partners. |
| In what companies Creo Medical Group invested in? | Creo Medical Group invested in IQ Endoscopes. |
See public comps similar to Creo Medical Group
Lists including Creo Medical Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.


